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A B S T R A C T
Isolated human populations represent good candidates for studying genetic and en-
vironmental causes of common complex diseases because of their decreased genetic and
environmental diversity. The possibility of inexpensive and reliable detection of disease
prevalence in such populations is therefore of considerable importance, as comprehen-
sive routine health data and disease registries are rarely available in these populations.
In this study, we validated the performance of the WHO Rose Angina Questionnaire
(RQ) in measuring the burden of coronary heart disease (CHD) in 9 settlements in these
Croatian Adriatic islands. CHD was defined as myocardial infarction (MI) diagnosed
by a specialist in the local general hospital, or angina pectoris (AP) by a local general
practitioner (GP). The »true« prevalence of CHD in 1,001 adult persons was 10.5%. The
results of the RQ screening based on the first 3, 5 and 6 questions were compared with
medical record of CHD. Increasing the number of RQ questions from 3 to 6 resulted in
decreasing test sensitivity (from 59.0% to 30.5%) and increasing test specificity (from
86.3% to 93.0%) in the prediction of true CHD status. CHD prevalence was overesti-
mated by 76% when subset of the first 3 questions of RQ was used and by 25% when the
first 5 questions were used. However, it was underestimated by 10% when the first 6
questions were used. We conclude that RQ is a useful screening method for measuring
burden of CHD in isolate human populations, and that the result based on the first 6
questions is a good approximation of the true CHD prevalence in the population, al-
though it should be considered a slight underestimate.
Key words: humans, isolate populations, burden of disease, prevalence, coronary
heart disease, WHO Rose angina questionnaire, screening, validity
205
Received for publication January 31, 2004
Introduction
Human isolate populations represent
good candidates for studying genetic and
environmental causes of common com-
plex diseases, due to decreased genetic
and environmental diversity1,2. Founder
effect, genetic drift and inbreeding are
population-genetic phenomena in human
isolates that can jointly lead to an in-
crease in the population frequencies of
rare genetic variants associated with sig-
nificantly increased disease risk. Conse-
quently, the prevalence of some complex
and monogenic diseases in certain sub-
isolates is increased in comparison with
the disease prevalence observed in gen-
eral population3. It is therefore important
that cheap and reliable methods of esti-
mating disease prevalence in such popu-
lations are defined, since comprehensive
routine health data and disease registries
are rarely available in these popula-
tions2. Detecting an increased prevalence
of some diseases in a specific sub-isolate
may also point to the action of a unique
environmental or lifestyle risk factor. Ra-
re genetic variants of large effect can
have similar effect on increased preva-
lence, which is desirable characteristic
for gene mapping using genetic associa-
tion studies4.
Coronary heart disease (CHD) is ma-
jor cause of death and disability and at-
tracts much attention from biomedical re-
search community5. The genetic basis of
susceptibility to CHD is subject of much
debate and still poorly understood6. To
begin any population-based investiga-
tions of genetic basis of CHD in human
isolate populations, a reliable screening
method to determine CHD prevalence ac-
curately, rapidly and inexpensively in the
field study would be needed. In this pa-
per, we aim to assess the performance of
WHO Rose angina questionnaire7 in esti-
mating burden of CHD in 9 settlements
from the Croatian Adriatic islands of Rab,
Vis, Mljet and Lastovo. This question-
naire has been used previously to assess
burden of CHD in geographic isolates8–11
and cultural isolates12,13, but with little
reference to its accuracy in predicting the




The Republic of Croatia has 15 Adri-
atic Sea islands with populations greater
than 1,000 inhabitants3. The settlements
on the islands are characterized by uni-
que population histories and they have
maintained isolation through centuries.
The Institute for Anthropological Research
in Zagreb, Croatia had investigated de-
mographic history and genetic structure
of island populations for last 50 years.
Results were reported in over 100 publi-
cations in international biomedical jour-
nals14–17. Recent population genetic in-
vestigations of Y-chromosomal and
mtDNA polymorphisms have confirmed
the conclusions of quantitative anthropo-
logical research conducted earlier18,19.
The potential of this isolate resource for
research into disease aetiology was then
outlined3 and confirmed through initial
successes in finding genetic basis of pre-
viously described monogenic (Mendelian)
diseases in these populations20,21. Fur-
ther research was designed to facilitate
studying of genetic architecture of com-
mon complex diseases of late onset (such
as cardiovascular diseases, cancer, diabe-
tes and psychiatric disorders)22–25.
The sample of the population has been
collected through fieldwork during 2002
and 2003. It involved research in 9 settle-
ments from the islands of Lastovo, Vis,
Mljet and Rab (Figure 1). They are con-
sidered to be geographically the most iso-
lated islands, which facilitated the effects
of founder effect and genetic drift on ge-
netic structure of the populations. The
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random sample of 100 adult inhabitants
was collected in each of the 9 settlements.
Sampling was based on the most com-
plete and accessible population registry
in each settlement, which included gen-
eral practitioner list (Mljet and Lastovo
islands), voting lists (Vis island) and hou-
sehold numbers (Rab island). An additio-
nal 101 examinees were recruited from
immigrants into all 9 settlements, to form
a genetically diverse control population.
All 1,001 examines were interviewed with
WHO Rose angina questionnaire (RQ, see
below) by medical doctor, and during in-
terview history of CHD was also obtained
from all examines. CHD was defined as
myocardial infarction (MI) diagnosed by
a specialist in the general hospital, or an-
gina pectoris (AP) by a local general prac-
titioner (GP), as described in an earlier
study25.
Modifications of WHO angina
questionnaire to assess CHD burden
We have recently noted26 that the cha-
racteristics of a screening test that make
it useful in clinical settings differ from its
use in population settings. In clinical set-
tings, it is of primary importance that the
screening method show high sensitivity.
In measuring disease burden in the popu-
lation, the key feature of the screening
method, such as RQ, is that the number
of false positives and false negatives is
similar, regardless of test sensitivity and
specificity. However, we showed that, over
a range of disease prevalences, high spec-
ificity of the test is an order of magnitude
more important than test sensitivity to
correctly assess population prevalence of
the disease26. As the interplay between
screening test sensitivity and specificity
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Fig. 1. Geographic location of the investigated islands of Rab, Vis, Lastovo and Mljet.
in providing similar number of false po-
sitives and false negatives is complex and
often counter-intuitive, in this study we
aimed to investigate the validity of RQ in
prediction of burden of CHD over a range
of sensitivity and specificity values.
The values of sensitivity and specific-
ity reported in the literature implied that
the use of all 7 RQ questions would result
in a considerable underestimate of popu-
lation prevalence of CHD26. Therefore, we
validated the performance of RQ in pre-
dicting the true CHD burden in the popu-
lation by using its three modifications:
based on the first 3 questions (Q1–3 ver-
sion), first 5 questions (Q1–5 version) and
first 6 questions (Q1–6 version). For de-
tails on the questions retained in each
modified version, and on how the results
of each version were scored, see Table 1.
Our expectation was that the modified
versions based on fewer questions would
be more sensitive and less specific, but
that increase in the number of questions
will lead to lower sensitivity and greater
specificity.
Statistical analysis
We calculated sensitivity (the propor-
tion of those with AP or MI in their medi-
cal records correctly identified as positive
by questionnaire); specificity (the propor-
tion of those with no diagnosis of AP or
MI in their medical records correctly
identified as negative by questionnaire);
positive predictive value (the proportion
of those identified by questionnaire as
having CHD who indeed had medical di-
agnosis of AP or MI), and negative predic-
tive value (the proportion of those identi-
fied by questionnaire as not having CHD
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TABLE 1
DEFINITION OF THREE MODIFICATIONS OF THE ORIGINAL WHO ROSE ANGINA
QUESTIONNAIRE ADJUSTED FOR SIMPLE USE IN VERBAL INTERVIEW TO ASSESS BURDEN
OF CORONARY HEART DISEASE IN ISOLATED POPULATIONS. THE INDEPENDENT
BACK-TRANSLATION FROM CROATIAN TO ENGLISH IS ALSO PROVIDED
Version Questions used Test positive if
Q1–3 Q1: Have you ever had any pain or discomfort in
your chest?
Q2: Do you get it when you walk uphill or hurry?
Q3: Do you get it when you walk at an ordinary
pace on the level?
Answers as follows:
Q1: yes
Q2 or Q3: yes
Q1–5 Version Q1–3 with two added questions:
Q4: What do you do if you get it while you are
walking?
Q5: If you are standing still, what happens to it?
Answers as follows:
As in Q1–3, and:
Q4: stop or slow down
Q5: relieved
Q1–6 Version Q1–5 with one added question:
Q6: How soon?
Answers as follows:
As in Q1–5, and:
Q6: 10 minutes or less
Back-translation
from Croatian:
Q1: Do you ever have any pain or discomfort in your chest?
Q2: When you walk uphill or hurry, does it produce the pain?
Q3: When you walk at an ordinary pace on the level, does it produce the pain?
Q4: What do you do if you get it while you are walking?
Q5: Do pain or discomfort in your chest go away if you stand still?
Q6: How long does it take them to go away?
who did not have medical diagnosis of AP
or MI) for each RQ modification. Based on
those parameters, we computed ratio of
test positives to »true« CHD cases in the
population under study, which would in
ideal case amount to 100%. Information
obtained from an interview and medical
records could be expressed as a 2×2 table
(Table 2) in which »CHD present« and
»CHD absent« represent the true state of
presence or absence of CHD (based on di-
agnoses from specialist/general practitio-
ner as described earlier). »CHD test posi-
tive« and »CHD test negative« represent
the test findings based on the result of
each RQ modification, according to the
criteria defined in Table 1. Cell »a« repre-
sents subjects with CHD (true positives)
who test positive, cell »b« subjects with
CHD (true positives) who test negative,
cell »c« subjects who do not have CHD
(true negatives) who test positive, and
cell »d« subjects who do not have CHD
(true negatives) and test negative. Test
sensitivity is given by a/(a+b); specificity
by d/(c+d); positive predictive value by
a/(a+c); negative predictive value by d/(b+d),
and prevalence of CHD by (a+b)/(a+b+
c+d) (Table 2). Finally, the ratio of CHD
test positives to true CHD cases, which is
a direct measure of over/underestimation
(in %) of true disease prevalence in the
population when each of the RQ modifica-
tions is applied, is calculated as sensitiv-
ity divided by positive predictive value26.
Results
The prevalence of CHD in 1,001 stud-
ied adult individuals in isolated popula-
tions of the islands of Rab, Vis, Lastovo
and Mljet, based on medical record from
specialists or general practitioners (GP),
was 10.5%. Table 3 shows the concor-
dance between definite CHD status and
its prediction by the three modified ver-
sions of WHO angina questionnaire. The
proportion of false negatives increased
from 4.3% to 7.3% with adding additional
questions to RQ, but the proportion of
false positives decreased from 12.3% to
6.3%. Nearly two-thirds of CHD positive
cases in population were correctly recog-
nised by modification of RQ based on first
3 questions, but less than a third when 6
questions were used.
Table 4 shows the validity of the three
RQ modifications. As predicted, RQ test
sensitivity declined from 59.0% to 30.5%
with introduction of additional questions,
while RQ test specificity increased from
86.3% to 93.0%. Interestingly, positive
predictive value of RQ peaked at 37.4%
when 5 questions (Q1–5) were used, while
negative predictive value was the great-
est with 3 questions used (Q1–3). Most
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TABLE 2
NOTATION AND DEFINITIONS OF TEST SENSITIVITY, SPECIFICITY, POSITIVE PREDICTIVE
VALUE, NEGATIVE PREDICTIVE VALUE AND DISEASE PREVALENCE IN THIS STUDY















value: a / (ac)
Negative predictive
value: d / (bd)
importantly, the ratio of RQ test positives
to CHD »actual« or »true« positives in the
studied population (or TAP ratio – see
ref.26) was 1.76 when 3 questions were
used, 1.25 with 5 questions and 0.90 with
6 questions. This suggests that, due to
the highest specificity regardless of the
low sensitivity, the RQ version based on 6
questions is best suited to measure the
prevalence of CHD in human isolate pop-
ulations. Caution should be taken as the
true population prevalence apparently
lies between the estimates based on 5 and
6 questions, so the assessment based on 6
questions should be treated as a slight
underestimate.
Discussion
The WHO Rose angina questionnaire
(sometimes also referred to as the London
School of Hygiene Cardiovascular Ques-
tionnaire) is widely used in epidemiologi-
cal studies as a screening tool and stand-
ardised method for assessing CHD bur-
den. It was developed in 1960's for as-
sessment of cardiovascular symptoms in
population survey, and since then it has
been used in many settings. The valida-
tion in former studies generally reported
high specificity (80–95%) with variable
levels of sensitivity (19–83%)12,27–29. Most
of the validation studies agree on the use-
fulness of RQ, but also highlight inaccu-
racies in cross-cultural assessments, in-
consistencies in repeatability, low predi-
ctive power of subsequent clinical events,
uncertain value of some questions and
lack of agreed standard diagnosis which
can be used to validate RQ12,27–32. The
values of sensitivity (30.5%) and specific-
ity (93.0%) obtained with the version ba-
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TABLE 3
CONCORDANCE BETWEEN DEFINITE CORONARY HEART DISEASE STATUS AND ITS PREDICTION
BY THE THREE MODIFIED VERSIONS OF WHO ANGINA QUESTIONNAIRE, ASSESSED IN
1,001 EXAMINEES FROM 9 ISLAND ISOLATES IN DALMATIA, CROATIA.
Q1–3 Q1–5 Q1–6

































VALIDITY OF THREE MODIFICATIONS TO THE WHO ANGINA QUESTIONNAIRE ASSESSED
IN 1,001 EXAMINEES FROM 9 ISLAND ISOLATES IN DALMATIA, CROATIA
Q1–3 Q1–5 Q1–6
Sensitivity 59.0% 46.7% 30.5%
Specificity 86.3% 90.8% 93.0%
Positive predictive value 33.5% 37.4% 33.7%
Negative predictive value 94.7% 93.6% 91.9%
Ratio of test to disease positives 1.76 1.25 0.90
sed on the first six RQ questions in our
study, which should be comparable to the
reported figures, fall within the expected
range.
The estimated prevalence of CHD us-
ing the full version of RQ ranged between
2.6% and 23.0% in the studies we re-
viewed8–13,27–32, but these estimates re-
lated to a variety of different age groups.
Studies that report estimates in age groups
similar to this study (18 years or older)
were rare, as many concentrated on el-
derly population samples. However, the
adjusted comparison shows that the fig-
ure of true CHD prevalence of 10.5% in
adult population in our study fall within
the upper third of the range of previous
reported analyses. Our results also imply
that the reported results of CHD preva-
lence measured by full version of the RQ
should probably be considered underesti-
mated by 10–20%. This study showed
that the value of true population preva-
lence lies between the results obtained by
asking five and 6 questions (of 7) of the
RQ. We concluded that using a shortened
version of the RQ based on first 6 ques-
tions in population studies is adequate to
estimate CHD burden in the population
not covered by a viable disease registry.
In the future, we aim to apply the
modification of RQ validated in this study
to determine the age and sex standard-
ised prevalence of CHD in further isolate
populations in these Croatian islands. We
would then propose to target settlements
showing significantly increased prevalen-
ce for further study in the expectation
that these populations may provide in-
sights into aetiology of this highly com-
plex, multifactorial disease33,34.
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U^INKOVITOST UPITNIKA SVJETSKE ZDRAVSTVENE ORGANIZACIJE
ZA ANGINU PECTORIS U MJERENJU PREVALENCIJE KORONARNE
BOLESTI SRCA U IZOLIRANIM LJUDSKIM POPULACIJAMA
S A @ E T A K
Izolirane ljudske populacije su zahvaljuju}i smanjenoj genetskoj i okoli{noj raznoli-
kosti prikladne za prou~avanje nasljednih i okoli{nih komponenti kroni~nih nezaraz-
nih bolesti. Zajedni~kim djelovanjem populacijsko-genetskih mehanizama poput u~in-
ka populacije utemeljitelja, genskog odstupanja i sro|ivanja genetska raznolikost je
smanjena, a u~estalosti rijetkih alela s visokim pripisivim rizikom za nastanak bolesti
su naj~e{}e pove}ane. Zbog spomenutih karakteristika i pove}ane u~estalosti nekih bo-
lesti, izolirane populacije su pogodne za mapiranje gena cije mutacije pove~avaju rizik
od kompleksnih i monogenskih bolesti. Naju~estalije bolesti ve}inom nisu obuhva}ene
djelovanjem populacijskih registara, stoga je mogu}nost jeftinog i pouzdanog odre|iva-
nja prevalencije bolesti u takvim populacijama od velikog zna~aja. U ovom istra`iva-
nju, procijenili smo u~inkovitost upitnika Svjetska zdravstvene organizacije za anginu
pectoris (SZO-AP) u mjerenju prevalencije koronarne bolesti srca (KBS) u 9 naselja na
hrvatskim otocima. Definitivna dijagnoza KBS postavljena je dijagnozom infarkta
miokarda od strane lije~nika specijalista u op}oj bolnici i/ili dijagnozom angine pectoris
mjesnog lije~nika obiteljske medicine. Prevalencija KBS u 1,001 odrasle osobe uklju-
~ene u istra`ivanje bila je 10,5%. Rezultati SZO-AP temeljeni na prvih 3, 5 ili 6 pitanja
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SZO-AP uspore|eni su s definitivnom dijagnozom KBS. Porast u broju pitanja SZO-AP
s 3 na 6 o~ekivano je rezultirao smanjenjem osjetljivo{}u screening-testa (s 59.0% na
30.5%) i porastom specifi~nosti (s 86.3% na 93.0%). Prevalencija KBS je precijenjena za
76% kada je odre|ivana pomo}u prva 3 pitanja iz SZO-AP, a za 25% kada je kori{teno
prvih 5 pitanja. Kada je kori{teno prvih 6 pitanja prevalencija KBS bila je podcijenjena
za 10%. Zaklju~ak je da je SZO-AP korisna metoda za procjenu prevalencije KBS u
izoliranim populacijama hrvatskih otoka, te da je rezultat testa koji koristi prvih 6
pitanja SZO-AP najbli`i to~noj prevalenciji KBS u populaciji.
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